Hemagen Diagnostics

Hemagen Diagnostics is a long-established, restructured diagnostics company pivoting to capitalize on two core markets: veterinary practice diagnostics and specialized human autoimmune/infectious disease testing. Following the sale of its Raichem clinical chemistry reagent business, the company is expanding through internal initiatives and strategic collaborations with major IVD distributors, particularly in Latin America and China. Its business model centers on manufacturing and distributing diagnostic kits and benchtop analyzers, aiming for growth through geographic expansion and partnership synergies.

Gold-standard diagnostic methodologies including Indirect Immunofluorescence Assay (IFA), Enzyme-Linked Immunosorbent Assay (ELISA), Hemagglutination (HA), and point-of-care (P.O.C.) formats. Also provides integrated benchtop analyzer systems (chemistry, hematology, electrolytes) for veterinary and human clinical use.

In veterinary diagnostics, Hemagen competes with giants like IDEXX Laboratories, Zoetis, and Heska (Antech). In human autoimmune and infectious disease testing, it faces competition from global IVD leaders such as Bio-Rad Laboratories, Werfen (Inova), and Thermo Fisher Scientific, as well as companies offering automated multiplexed assay systems. Its strategy is to compete on quality, specific test menu, and distributor relationships rather than head-on platform battles.